Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase. 2001

K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
Department of Pediatrics, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland. katja.peltola@utu.fi

OBJECTIVE To investigate clinical variation in a genetically homogenous group of subjects with gyrate atrophy of choroid and retina with hyperornithinemia (GA). The group was made up of homozygotes and compound heterozygotes for mutation L402P in the ornithine aminotransferase (OAT) gene. METHODS Cross-sectional study. METHODS Thirty-five Finnish subjects (18 men) with GA with a mean age of 33 years (range, 5-74 years) carrying the Finnish founder mutation L402P. METHODS All subjects were examined between 1993 and 1995. The analysis was composed of, in addition to careful clinical evaluation, studies of visual fields with Goldmann perimeter, photographing of the eye fundi, and corneal electroretinography (ERG) recordings. METHODS The changes in eye fundi, visual acuity, cataract changes in the lens, visual field constriction, and ERG responses were determined. RESULTS Myopia, early cataracts, and highly abnormal ERG were typical for the GA subjects. The changes progressed rather uniformly with age. However, visual acuity, funduscopic findings, and visual fields showed great phenotypic variation. Despite the great interindividual variation, both eyes of each subject were always similarly affected. CONCLUSIONS This study of 35 subjects with GA carrying a single mutation shows that the ophthalmologic symptoms and findings vary widely. The data also reveal that GA subjects are already affected by severe visual impairment in young adulthood. However, the diagnosis is often made very late.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009216 Myopia A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness. Nearsightedness,Myopias,Nearsightednesses
D009952 Ornithine An amino acid produced in the urea cycle by the splitting off of urea from arginine. 2,5-Diaminopentanoic Acid,Ornithine Dihydrochloride, (L)-Isomer,Ornithine Hydrochloride, (D)-Isomer,Ornithine Hydrochloride, (DL)-Isomer,Ornithine Hydrochloride, (L)-Isomer,Ornithine Monoacetate, (L)-Isomer,Ornithine Monohydrobromide, (L)-Isomer,Ornithine Monohydrochloride, (D)-Isomer,Ornithine Monohydrochloride, (DL)-Isomer,Ornithine Phosphate (1:1), (L)-Isomer,Ornithine Sulfate (1:1), (L)-Isomer,Ornithine, (D)-Isomer,Ornithine, (DL)-Isomer,Ornithine, (L)-Isomer,2,5 Diaminopentanoic Acid
D009953 Ornithine-Oxo-Acid Transaminase A pyridoxal phosphate enzyme that catalyzes the formation of glutamate gamma-semialdehyde and an L-amino acid from L-ornithine and a 2-keto-acid. EC 2.6.1.13. Ornithine Aminotransferase,Ornithine Transaminase,L-Ornithine-2-Oxo-Acid Aminotransferase,L-Ornithine-2-Oxoglutarate Aminotransferase,Ornithine Ketoacid Aminotransferase,Ornithine-2-Ketoglutarate Aminotransferase,Ornithine-Keto-Acid-Transaminase,Ornithine-Ketoacid-Transaminase,Pyrroline-5-Carboxylate Synthase,Aminotransferase, L-Ornithine-2-Oxo-Acid,Aminotransferase, L-Ornithine-2-Oxoglutarate,Aminotransferase, Ornithine,Aminotransferase, Ornithine Ketoacid,Aminotransferase, Ornithine-2-Ketoglutarate,Ketoacid Aminotransferase, Ornithine,L Ornithine 2 Oxo Acid Aminotransferase,L Ornithine 2 Oxoglutarate Aminotransferase,Ornithine 2 Ketoglutarate Aminotransferase,Ornithine Keto Acid Transaminase,Ornithine Ketoacid Transaminase,Ornithine Oxo Acid Transaminase,Pyrroline 5 Carboxylate Synthase,Synthase, Pyrroline-5-Carboxylate,Transaminase, Ornithine,Transaminase, Ornithine-Oxo-Acid
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D002386 Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed) Cataract, Membranous,Lens Opacities,Pseudoaphakia,Cataracts,Cataracts, Membranous,Lens Opacity,Membranous Cataract,Membranous Cataracts,Opacities, Lens,Opacity, Lens,Pseudoaphakias
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
February 1988, The Journal of clinical investigation,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
November 1977, Proceedings of the National Academy of Sciences of the United States of America,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
February 1991, Molecular biology & medicine,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
January 1980, Neurochemistry international,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
November 1977, The New England journal of medicine,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
September 1998, Pediatric research,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
September 2021, European journal of ophthalmology,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
May 1973, Lancet (London, England),
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
January 1984, Clinica chimica acta; international journal of clinical chemistry,
K E Peltola, and K Näntö-Salonen, and O J Heinonen, and S Jääskeläinen, and K Heinänen, and O Simell, and E Nikoskelainen
January 1975, Transactions of the American Ophthalmological Society,
Copied contents to your clipboard!